Suzanne Bhatt

Suzanne Bhatt focuses on next-generation proteasome inhibitors including carfilzomib and their mechanisms of inducing lethal ER stress in cancer cells. Her research has characterized how irreversible proteasome inhibition by carfilzomib creates more profound and sustained UPR activation compared to bortezomib, contributing to its activity in bortezomib-resistant disease. She has investigated resistance mechanisms to carfilzomib including adaptive UPR remodeling that allows cancer cells to tolerate proteasome inhibition. Her clinical research has contributed to the establishment of carfilzomib-based regimens in myeloma.